Evidence map›Paper›PMID 37177864›Full record

ArticleClinical and translational science2023

Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease.

Sebastiaan J W van Kraaij, Diana R Pereira, Bastiaan Smal, Luciana Summo, Anne Konkel, Janine Lossie, Andreas Busjahn, Tom N Grammatopoulos, Erica Klaassen, Robert Fischer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Sebastiaan J W van KraaijCentre for Human Drug Research, Leiden, The Netherlands.ORCID 0000-0002-2465-1831
Diana R PereiraCentre for Human Drug Research, Leiden, The Netherlands.
Bastiaan SmalCentre for Human Drug Research, Leiden, The Netherlands.
Luciana SummoOMEICOS Therapeutics GmbH, Berlin, Germany.
Anne KonkelOMEICOS Therapeutics GmbH, Berlin, Germany.
Janine LossieOMEICOS Therapeutics GmbH, Berlin, Germany.
Andreas BusjahnHealthTwiSt GmbH, Berlin, Germany.
Tom N GrammatopoulosBioEnergetics LLC, Boston, Massachusetts, USA.
Erica KlaassenCentre for Human Drug Research, Leiden, The Netherlands.ORCID 0000-0003-0089-1846
Robert FischerOMEICOS Therapeutics GmbH, Berlin, Germany.
Wolf-Hagen SchunckOMEICOS Therapeutics GmbH, Berlin, Germany.
Pim GalCentre for Human Drug Research, Leiden, The Netherlands.ORCID 0000-0001-7622-9029
Matthijs MoerlandCentre for Human Drug Research, Leiden, The Netherlands.
Silence Therapeutics (Germany) · DECentre for Human Drug Research · NLLeiden University Medical Center · NLBioEnergetics (United States) · USMax Delbrück Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of pharmacological therapies for mitochondrial diseases is hampered by the lack of tissue-level and circulating biomarkers reflecting effects of compounds on endothelial and mitochondrial function. This phase 0 study aimed to identify biomarkers differentiating between patients with mitochondrial disease and healthy volunteers (HVs). In this cross-sectional case-control study, eight participants with mitochondrial disease and eight HVs matched on age, sex, and body mass index underwent study assessments consisting of blood collection for evaluation of plasma and serum biomarkers, mitochondrial function in peripheral blood mononuclear cells (PBMCs), and an array of imaging methods for assessment of (micro)circulation. Plasma biomarkers GDF-15, IL-6, NT-proBNP, and cTNI were significantly elevated in patients compared to HVs, as were several clinical chemistry and hematology markers. No differences between groups were found for mitochondrial membrane potential, mitochondrial reactive oxygen production, oxygen consumption rate, or extracellular acidification rate in PBMCs. Imaging revealed significantly higher nicotinamide-adenine-dinucleotide-hydrogen (NADH) content in skin as well as reduced passive leg movement-induced hyperemia in patients. This study confirmed results of earlier studies regarding plasma biomarkers in mitochondrial disease and identified several imaging techniques that could detect functional differences at the tissue level between participants with mitochondrial disease and HVs. However, assays of mitochondrial function in PBMCs did not show differences between participants with mitochondrial disease and HVs, possibly reflecting compensatory mechanisms and heterogeneity in mutational load. In future clinical trials, using a mix of imaging and blood-based biomarkers may be advisable, as well as combining these with an in vivo challenge to disturb homeostasis.

Indexed as

Leukocytes, MononuclearMitochondrial DiseasesBiomarkersCase-Control StudiesCross-Sectional StudiesHumansMitochondriaBiomarkers

Identifiers

PMID37177864
PMCPMC10339694
OpenAlexW4376598489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.